RxDoctor Payments Data

Paul Welch, MD

Nephrology · Martinsburg, WVNPI 1548259146

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $89 of the $120 with a category attached, or 74.4%. 5 manufacturers reported payments, led by Fresenius USA Marketing, Inc. at 32.2% of the total. Reporting peaked in 2024 at $65 and has fallen 93.6% since, to $4 in 2025. That places this record below the midpoint for nephrology clinicians in WV, where the typical reported total is $740.

$120in general payments, 2019–2025

Across 10 payments — averaging $11.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$39
  • Travere Therapeutics, Inc.$31
  • Sanofi$24
  • Amgen$14
  • Strongbridge US Inc.$12

What the payments were for

  • Food & beverage$8974%
  • Education$3126%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$120 in reported general payments places this provider in the 15th percentile of 55 nephrology providers in West Virginia.

See all nephrology providers in West Virginia

Medicare billing

Part B allowed, 2024
$296,134
Medicare patients
531
Services billed
2,008

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin410$345,199
TrulicityDulaglutide76$95,303
XphozahTenapanor Hcl12$61,435
VelphoroSucroferric Oxyhydroxide17$50,847
OzempicSemaglutide37$42,467
FarxigaDapagliflozin Propanediol41$36,296
MounjaroTirzepatide24$24,487
Cinacalcet Hcl79$18,678
Calcitriol690$13,191
Sevelamer Carbonate34$7,235
DapagliflozinDapagliflozin Propanediol12$3,805
Mycophenolate Mofetil25$2,118
Losartan Potassium187$1,764
Famotidine135$1,534
Spironolactone152$1,083

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$39$50,84717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 55 nephrology providers in West Virginia.

Other nephrology in Martinsburg

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →